Showing posts with label Awards. Show all posts
Showing posts with label Awards. Show all posts

Sunday, April 10, 2011

American Optometric Association Awards ACUVUE(R) ADVANCE(R) Plus Brand Contact Lenses With Seal Of Acceptance For UV Absorbing Contact Lenses


Main Category: Eye Health / Blindness
Article Date: 18 Mar 2011 - 2:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
not yet ratednot yet rated
ACUVUE® ADVANCE® Plus Brand Contact Lenses became the sixth contact lens in the ACUVUE® Brand family of products to receive the Seal of Acceptance for Ultraviolet Absorbing Contact Lenses from the American Optometric Association's (AOA) Commission on Ophthalmic Standards.

In awarding the Seal of Acceptance, AOA's Commission on Ophthalmic Standards, which provides independent evaluation of ophthalmic related products, determined that ACUVUE® ADVANCE® Plus Brand meets AOA specifications for ultraviolet absorbing contact lenses. These specifications are in accordance with published standards of the American National Standards Institute (ANSI) and International Standards Organization (ISO).

"For those who need vision correction, a significant measure of UV protection can be achieved with a combination of UV-absorbing sunglasses, a wide-brimmed hat, and UV-blocking contact lenses," says Karl M. Citek, OD, Ph.D., Chair of the Commission on Ophthalmic Standards.

"Not all contact lens lines offer UV protection, and, of those that do, not all provide similar absorption levels," explains Sheila Hickson-Curran, Director, Medical Affairs, VISTAKON®, Division of Johnson & Johnson Vision Care, Inc.

All ACUVUE® Brand Contact Lenses offer effective UV-blocking, and among contact lens brands, only ACUVUE® ADVANCE® Plus, 1•DAY ACUVUE® TRUEYETM, ACUVUE® OASYS® with HYDRACLEAR® PLUS, ACUVUE® OASYS®for ASTIGMATISM, ACUVUE® ADVANCE® with HYDRACLEAR®, and ACUVUE® ADVANCE® for ASTIGMATISM Brand Contact Lenses carry the AOA's Seal of Acceptance for Ultraviolet Absorbing Contact Lenses. These contact lenses offer the highest level of UV-blocking available, blocking more than 90 percent of UVA rays and 99 percent of UVB rays that reach the lens.† * On average, contact lenses without UV-blocking capability allow 90% of UVA radiation and 70% of UVB radiation to pass through the lenses to your eyes.

"Although UV-blocking contact lenses provide important added protection for patients, they should not be viewed as a stand-alone solution," notes Dr. Citek. "Contact lenses should always be worn in conjunction with high-quality UV-blocking sunglasses and a wide-brimmed hat for maximum UV protection for the eyes."

Important information for contact lens wearers: ACUVUE® Brand Contact Lenses are available by prescription only for vision correction. An eye care professional will determine whether contact lenses are right for you. Although rare, serious eye problems can develop while wearing contact lenses. To help avoid these problems, follow the wear and replacement schedule and the lens care instructions provided by your eye doctor. Do not wear contact lenses if you have an eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. If one of these conditions occurs, contact your eye doctor immediately.

† Helps protect against transmission of harmful UV radiation to the cornea and into the eye.

* WARNING: UV-absorbing contact lenses are NOT substitutes for protective UV-absorbing eyewear such as UV-absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. You should continue to use UV-absorbing eyewear as directed. NOTE: Long term exposure to UV radiation is one of the risk factors associated with cataracts. Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of outdoor activities). UV-Blocking contact lenses help provide protection against harmful UV radiation. However, clinical studies have not been done to demonstrate that wearing UV-Blocking contact lenses reduces the risk of developing cataracts or other eye disorders. Consult your eye care practitioner for more information.

Source:
Johnson & Johnson Services, Inc.

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

Sunday, April 3, 2011

Researchers Receive NIMH Brain Awards


Main Category: Mental Health
Also Included In: Psychology / Psychiatry;  Eating Disorders;  Obesity / Weight Loss / Fitness
Article Date: 09 Feb 2011 - 0:00 PST window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
3 starsnot yet rated
Two Boston University School of Medicine (BUSM) faculty members, Pietro Cottone, PhD, an assistant professor of pharmacology and psychiatry and Michael Silverstein, MD, an associate professor of pediatrics, were each awarded the prestigious National Institute of Mental Health (NIMH) Biobehavioral Research Awards for Innovative New Scientisits (BRAINS) grant with ten other investigators from around the country. The BRAINS award called for innovative and groundbreaking research projects from early stage investigators to explore the complex mechanisms underlying mental disorders or novel treatments and prevention strategies.

The BRAINS initiative was created to support the research programs and career development of outstanding scientists who are in the early, formative stages of their careers and who plan to make a long term commitment to research most relevant to NIMH. This award seeks to assist these individuals in launching an innovative clinical, translational, or basic research program that holds the potential to profoundly transform the understanding, diagnosis, treatment, or prevention of mental disorders.

Cottone, whose research explores the neural mechanisms underlying addictive disorders summarizes his proposal. "We propose that a history of dieting and relapse represents a vicious circle between stress and compulsive eating. In other words, the next attempt to avoid junk food is going to be more painful and stressful than the previous one, and the likelihood of relapse will progressively increase. We propose that during dieting the endocannabinoids (chemicals of the brains that protect from stress and promote the consumption of our favorite foods) are released to try to fight this stressful condition but on the other side they also increase our craving for junk food. Therefore blockade of the endocannabinoid action on one hand reduces compulsive eating, but on the other hand it induces anxiety and depression. This proposal will clarify the mechanisms linking eating disorders and obesity to anxiety and mood disorders."

Silverstein is studying maternal depression and is exploring detection and treatment options in the community setting, using for example, programs like Head Start and Early Intervention. He is experimenting with motivational interviewing and cognitive behavior therapy. "Our project is a community-based maternal depression prevention trial that enrolls young mothers at risk for developing major depressive disorder. The project takes place in Head Start and aims to enroll 230 women over five years."

"While these awards fund specific projects, they are truly an investment in specific people," said NIMH director Thomas R. Insel, MD. Inspired by the success of the NIH Director's Pioneer Awards and New Innovator Awards, both of which are designed to provide support for innovative research that has the potential for unusually high impact on health science. "The hope is that BRAINS awards will give early stage investigators enough flexibility to take risks on tough problems that are central to neuroscience and to the understanding of mental illness, such as the nature and development of neural circuits and the genetic factors and environmental influences that both shape and disrupt them," he adds.

The BRAINS program awards up to $1.625 million over five years for early career scientists focusing on a gap area identified in the Institute's Strategic Plan.

Source:
Gina DiGravio
Boston University Medical Center

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here